Maybe it would be better if it hadn't been mentioned. The Writer just repeated the things she said in a previous article about Amarin. She's clearly been affected by those doing the "injection" study because they want to minimize Amarin, which they surely view as a competitor. I guess Amarin didn't respond to the first article by sending her the facts on MO and what the FDA found in its study.
Anyhow, here's what the WSJ article says about Amarin and Vascepa today:
"Questions have emerged about the effectiveness of a fish oil-derived prescription drug called Vascepa. The drug is made of a high dose of a purified form of the omega-3 fatty acid eicosapentaenoic acid, or EPA. In 2019, the U.S. Food and Drug Administration approved it to reduce the risk of heart attacks, strokes and other serious cardiovascular-disease events in patients with elevated triglyceride levels who are at high risk and on cholesterol-lowering drugs.
Some researchers say that the placebo used in a large clinical trial of Vascepa may have raised the heart-disease risk for people who took it, making the benefit from Vascepa look larger than it would otherwise have been. Data from a recent analysis appeared to suggest that.
Amarin Corp., maker of the drug, said it stands by the results of the trial and doesn’t plan to replicate it. The placebo’s effects were small, in absolute terms, and didn’t exaggerate Vascepa’s benefits, the company said."
Market Data 
Markets 
AI
